GeNeuro Phase 2 multiple sclerosis trial update

Geneva, Switzerland, March 19, 2020 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on understanding and stopping the causal factors driving the progression of neurodegenerative and autoimmune diseases, today announced the temporary postponement of its planned Phase 2 trial of temelimab in multiple sclerosis (MS) at the Karolinska Institutet’s Academic […]